Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





Ethylene Dibromide (EDB) (Revised)										Related Pages
										October 1981
DHHS (NIOSH) Publication Number 82-105
Current Intelligence Bulletin 37

The National Institute for Occupational Safety and Health (NIOSH) reaffirms its 1977 recommendation that ethylene dibromide be treated as a potential-occupational carcinogen in the workplace. This includes a ceiling limit of 0.13 ppm (1.0 mg/m3) as determined over any 15-minute sampling period and use of appropriate controls to reduce worker exposure. Recent animal studies involved exposure to ethylene dibromide by skin application, oral administration, and inhalation. Statistically significant increases in tumors of the respiratory tract, mammary gland, spleen, and nasal cavity were observed. Inhalation studies with rats and mice at ethylene dibromide concentrations below the current Occupational Safety and Health Administration (OSHA) permissible exposure limit (PEL) of 20 ppm demonstrated a carcinogenic risk. In addition, the new animal bioassay studies reaffirm the increased toxic effects reported in 1978 when EDB is administered with disulfiram, a widely-used drug in alcoholism control programs. This increased interaction may note necessarily be restricted to disulfiram, but may occur with similarly structured compounds such as Thiram, a fungicide and seed disinfectant.

Background
Purpose of Bulletin
This Bulletin is being released because of the anticipated increased use of EDB as a fruit fumigant, and to alert workers who may have a potential EDB exposure to recent information about its potential carcinogenic risk. This information reinforces NIOSH’s 1977 assessment that EDB is highly toxic and may cause cancer in humans.1 In the 1977 assessment, NIOSH concluded that persons chronically exposed to EDB may be at increased risk of adverse reproductive and other effects. Evidence from animal experiments indicates that these effects may include sterility, inheritable changes in offspring, teratogenesis, and adverse effects on the liver, kidneys, heart, and other internal organs. Skin contact with EDB was found to produce chemical burns as well as systemic effects from percutaneous absorption.
Production and Use
EDB was first produced on a commercial scale during the mid-1920’s. Current U.S. production is estimated at approximately 300 million pounds annually. EDB is used primarily as a scavenger in leaded fuels in combination with ethylene dichloride. These scavengers are used to form volatile lead compounds during combustion, which are more completely removed from the combustion chambers This usage is decreasing as the consumption of leaded gasoline declines. EDB is also used as a soil, grain, and fruit fumigant, as an intermediate in the synthesis of dyes and pharmaceuticals, and as a solvent for resins, gums, and waxes. NIOSH estimates that approximately 108,000 U.S. workers are potentially exposed to EDB during its production and use. In addition, an estimated 875,000 workers are potentially exposed to very low levels of EDB while working with leaded gasoline.2
Exposure Standards and Guides
OSHA’s current standard for occupational exposure to EDB is 20 ppm as a time-weighted average (TWA) concentration for an 8-hour work shift, with an acceptable ceiling concentration of 30 ppm. A maximum peak above the acceptable ceiling concentration for an 8-hour work shift of 50 ppm for not more than 5 minutes is also permitted (29 CFR 1910.1000). This standard was adopted from the American National Standards Institute recommendation (ANSI Z37.31-1970).
In 1977, NIOSH recommended that occupational exposure to EDB be limited to a ceiling concentration of 0.13 ppm (1.0 mg/m3), as determined over any 15-minute sampling period.1
In 1978, the American Conference of Governmental Industrial Hygienists (ACGIH) voided their 20-ppm threshold limit value (TLV) recommendation and assigned EDB an Alb classification (Human Carcinogen) without a TLV. After further review of the data in 1980, the ACGIH changed the classification to A2 (Industrial Substances Suspect of Carcinogenic Potential for Man). No TLV for EDB is assigned.3
In addition, California’s Division of Occupational Safety and Health (Cal/OSHA) has had an Emergency Temporary Standard of 0.13 ppm adopted that became effective September 23, 1981. If this level is not rejected by the California Office of Administrative Law, it will remain in effect for 120 days. This is the same level recommended by NIOSH in 1977.
Extent of Exposures
Most of the environmental data on EDB came from the monitoring of exposures at EDB manufacturing operations, gasoline production and distribution facilities, and fruit fumigation operations.
NIOSH performed an industrial hygiene survey of two manufacturing and two user facilities of EDB. Samples were taken for more than 69 potentially-exposed workers in 17 job classifications. Median EDB exposures by similar job types in the manufacturing processes ranged from 0.010 to 0.5 ppm (35 TWA personal samples), and 0.0002-0.054 ppm in antiknock blending operations (39 TWA personal samples). General area samples collected at breathing zone heights had median TWA levels of 0.2 ppm for 10 samples at process sites, and 0.5 ppm for 3 samples at laboratory sites.
For quality control samples, EDB ceiling levels ranged from 0.04 to 23.4 ppm; for loading and unloading of tank cars, they were 0.09-2.4 ppm.4
A NIOSH environmental survey of fruit fumigation operations reported worker exposure (personal samples) to EDB ranging from nondetectable (8 of 29 samples) to 2.92 ppm for a post fumigation fruit loader in the transport truck trailer. Forklift operator exposures ranged from 0.06 to 2.08 ppm. Area samples of airborne EDB concentrations ranged from nondetectable (13 of 33 samples) to 2.96 ppm at the EDB introduction point into the fumigation chamber.
In another survey, conducted at three fruit packing plants, personal and area air samples were collected for the determination of EDB exposures. Of the 14 personal samples collected, EDB was nondetectable in 13 samples, with the other indicating a concentration of 0.14 ppm for a fumigator. Area sample airborne EDB concentrations ranged from nondetectable (16 of 20 samples) up to 0.81 ppm for a sample collected at the door of the fumigation chamber.6

Toxicity
Evidence of Carcinogenicity in Experimental Animals
In 1977, NIOSH reported the preliminary results of a National Cancer Institute (NCI) study that indicated potential carcinogenic effects in rats and mice when EDB was administered by gavage.7 The completed bioassay was reported in 1978.8 Under the conditions of this bioassay, EDB was carcinogenic to Osborne-Mendel rats and B6C3Fl mice. Additional animal carcinogenicity bioassays have been conducted since then to assess the carcinogenic potential of EDB by inhalation and skin absorption.
Van Duuren et al. reported in 1979 an increased incidence of skin papillomas, skin carcinomas, and lung tumors in treated male and female noninbred Ha:ICR Swiss mice. The animals received repeated skin applications of EDB 3 times weekly for 40-594 days at 25 or 50 mg/application/mouse. This was the first reported study demonstrating EDB to be carcinogenic by skin applications.9
The National Toxicology Program (NTP) and NCI recently reported the results of a carcinogenesis bioassay of EDB by the inhalation route.10 Groups of rats and mice of each sex were exposed to airborne EDB it concentrations of 10 and 40 ppm, levels below and above OSHA’s PEL of 20 ppm. Animals were exposed 6 hours/day, 5 days/week for 78-103 weeks.
In this bioassay, EDB was found to be carcinogenic for rats at both the 10- and 40-ppm dosages, causing increased incidences of tumors of the nasal cavity and adenomas of the pituitary gland in males and females, hemangiosarcomas of the circulatory system and mesotheliomas in the tunica vaginalis in males, and fibroadenomas of the mammary gland in females. Likewise, EDB was carcinogenic for mice at both dosages, causing increased incidences of alveolar/bronchiolar carcinomas in males and females, and fibrosarcomas in the subcutaneous tissue, hemangiosarcomas of the circulatory system, tumors of the nasal cavity, and adenocarcinomas of the mammary gland in females.
Concurrent with the NTP and NCI study, NIOSH sponsored a study on EDB’s chronic inhalation toxicity in rats.11 The study was designed to determine the effects of EDB inhalation at OSHA’s current PEL of 20 ppm, with and without disulfiram in the diet. Rats were exposed 7 hours/day, 5 days/week, for 18 months to simulate occupational exposure to EDB.
The results showed a high mortality rate and a statistically significant increase in the incidence of benign and malignant tumors of the spleen, mammary gland, and nasal cavity for rats exposed by inhalation to EDB at 20 ppm and fed the standard rat diet. Rats exposed by inhalation at 20 ppm and fed the diet containing 0.05% disulfiram by weight exhibited a higher mortality rate, as well as an earlier development and a statistically significant increased incidence of tumors of the liver and mesentery compared with those animals exposed to EDB alone.
These data10,11 demonstrate EDB to be carcinogenic in rats and mice when exposed by inhalation. The data also show that the addition of disulfiram to the diet results in approximately a ten-fold increase in the incidence of hepatocellular carcinomas over exposure to EDB alone. EDB has also been shown to be carcinogenic in mice as a result of percutaneous absorption.9
Epidemiologic Evidence of Cancer in Humans
The epidemiologic studies of EDB reported in the literature are inconclusive because they suffer from small cohort size, incomplete or missing exposure data, and insufficient latencies to observe carcinogenic effects.
In 1980, a retrospective mortality study of 161 workers (99 in Plant A and 63 in Plant B) exposed to EDB at two EDB manufacturing plants, was reported. The results indicated an observed increase in deaths due to malignant neoplasms and nonmalignant respiratory disease among the workers from Plant B. However, when the data from both plants were combined, no significant increase in mortality was observed.12 In another study only one death was observed in a group of 53 workers potentially exposed to EDB in a chemical manufacturing plant. The cause was listed as cancer of the kidney.13
In studies of the effect of EDB exposure on sperm production conducted in 1977 and 1978, sperm counts were performed on 59 workers potentially exposed to EDB in a chemical manufacturing plant. The author concluded that exposures to EDB at the levels found for this population (less than 5.0 ppm) had no adverse effect on sperm counts. Neither possible confounding exposures nor the health of the individuals was discussed. No tests were performed to determine sperm motility, penetrance, morphology, or density or to evaluate other sperm function parameters.13
In 1979, a retrospective evaluation of the reproductive histories of exposed workers at four EDB manufacturing plants was published. The authors assessed the reproductive histories in terms of the number of live births in 297 wives of workers. The observed number of live births (only 50% of the expected value) was significantly lower than expected at one of the four plants.
However, the employees at this plant had 22 known surgical and nonsurgical sterilizations, the highest rate of the four plants. No significant difference was observed in expected births at the other three plants. No information was given on total conceptions, including spontaneous or induced abortions, among workers’ wives.14
Evidence of Mutagenicity
A 1979 study reported that gaseous EDB at concentrations ranging from 0.2 2 ppm induced significant numbers of sex-linked recessive lethal mutations in Drosophila melanogaster males. Mutation induction was directly proportional to both exposure time and exposure concentration up to 60 ppm-hours, for all cell stages tested. This genetic evidence is in concordance with the irreversible, cumulative nature of EDB toxicity.15

Recommendations
The recent experimental data reinforce NIOSH’s 1977 conclusion that ethylene dibromide is carcinogenic in animals. Ethylene dibromide has been shown to cause significant increases in tumors of the respiratory tract, mammary gland, spleen, and nasal cavity when administered to animals by skin application, gavage, or inhalation. Furthermore, the data confirm that when disulfiram is administered concurrently with EDB both its toxicity and carcinogenicity are enhanced. As was reported in 1978 by NIOSH, the interaction of EDB and disulfiram warrants a special precaution, and measures should be taken to prevent any individual from being exposed to both substances at the same time.16 This increased interaction may not necessarily be restricted to disulfiram, but may occur with similarly structured compounds such as Thiram.
Although humans and animals may differ in their susceptibilities to specific chemical compounds, any substance that produces cancer in experimental animals should be considered a potential human carcinogen.
NIOSH urges employers to voluntarily assess the conditions under which their workers may be exposed to EDB, especially with concurrent exposures to disulfiram or other similarly structured chemicals, such as Thiram. NIOSH reaffirms its 1977 recommended workplace environmental limit of 0.13 ppm. Employers should regard this level as the upper boundary of exposure and make every effort to maintain the exposure as low as is technically feasible.
*[signature]*
J. Donald Millar, M.D.
Assistant Surgeon General
Director

References
National Institute for Occupational Safety and Health: *Criteria for a Recommended Standard...... Occupational Exposure to Ethylene Dibromide.* DHEW (NIOSH) Publication No. 77-221, 208 pp. (1977).
National Institute for Occupational Safety and Health: *National Occupational Hazard Survey Quarterly Hazard Summary Report.* NIOSH, Cincinnati, OH, 145 pp., August 6, 1980. Unpublished data.
American Conference of Governmental Industrial Hygienists: *Documentation of the Threshold Limit Values*, 4th ed., pp. 180-181, Cincinnati, OH (1980).
Rumsey, D.W. and R.K. Tanita. *An Industrywide Industrial Hygiene Study of Ethylene Dibromide.* DHEW (NIOSH) Publication No. 79-112, 57 pp. (1978).
National Institute for Occupational Safety and Health: *Technical Assistance Report No, 80-17,* with USDA, Rio Crande Valley, TX. NIOSH, Cincinnati, OH (1981).
National Institute for Occupational Safety and Health: *Technical Assistance Report No. TA-80-2,* with USDA, Hilo, HI. NIOSH, Cincinnati, OH (1980).
Olson, W.A., R .T. Habermann, E.K. Weisburger, J.M. Ward and H. H. Weisburger. Induction of Stomach Cancer in Rats and Mice by Halogenated Aliphatic Fumigants. *J. Nat. Cancer Inst. 51*:1993-1995 (1973).
National Cancer Institute: *Bioassay of 1,2-Dibromoethane for Possible Carcinogenicity,* TR-86 (CAS No. 106-93-4). Carcinogenesis Testing Program. DHEW Publication No. (NIH) 78-1336, 64 pp. (1978).
Van Duuren, B.L., B.M. Goldschmidt, G. Loewengart, A.C. Smith, S. Melchlonne, I. Seidman, and D. Roth. Carcinogenicity of Halogenated Olefinic and Aliphatic Hydrocarbons in Mice. *J. Nat. Cancer Inst. 63*(6):1433-1439 (1979).
National Cancer Institute: *Carcinogenesis Bioassay of 1,2-Dibromoethane (Inhalation Study),* TR-210 (CAS. No., 106-93-4). Carcinogenesis Testing Program. DHHS Publication No. (NIH) 81-1766 (1981).
Wong, L.C.K., J.M, Winston, C. B. Hong, and J. Hagensen. *Chronic Inhalation Toxicity of 1,2-Dibromoethane in Rats With and Without Dietary Disulfiram*, Kansas City, MO. Niosh contract no 210-76-0131 revised by H. Plotnick, NIOSH, Cincinnati, OH (1980). Unpublished.
Ott, M.G., H.C. Scharneweber, and R.R. Langner. Mortality Experience of 161 Employees Exposed to Ethylene Dibromide in Two Production Units. *Br. J. Ind. Med. 37*:163-168 (1980).
Ter Haar, G. An Investigation of Possible Sterility and Health Effects from Exposure to Ethylene Dibromide, in *Banbury Report 5–Ethylene Dichloride: A Potential Health Risk?*, pp. 167-188. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1980).
Wong, O., H.M.D. Utidjian, and V.S. Karten. Retrospective Evaluation of Reproductive Performance of Workers Exposed to Ethylene Dibromide (EDB). *J. Occup. Med. 21*:98-102 (1979).
Kale, P.G. and J.W. Baum. Sensitivity of *Drosophila Melanogaster* to Low Concentrations of Gaseous Mutagens–II. Chronic Exposures. *Mutate Res. 68*:59-68 (1979).
*Current Intelligence Bulletin Reprints – Bulletins 19 through 30 for 1978*. DHEW (NIOSH) Publication No. 79-146, pp. 45-49 (1979).
Appendix I: Identifiers and Synonyms for Ethylene Dibromide
Chemical Abstracts Service Registry Number: 106-93-4
NIOSH RTECS Number: KH92750
Chemical Formula: C2H4Br2
Aadibroom
Bromofume
Celmide
Dibromoethane
1,2-Dibromoethane
*sym*-Dibromoethane
Dowfume EDB
Dowfume MC-2
Dowfume W-8
Dowfume W-85
Dowfume 40
E-D-BEE
EDB
EDB-85
ENT 15,349
Ethylene Bromide
Ethylene Dibromide
Fumo-Gas
Glycol Dibromide
Iscobrome D
Kopfume
Nefis
Pestmaster
Pestmaster EDB-85
Sanhyuum
Soilbrum-40
Soilbrum-85
Soilfume
Unifume
Appendix II: Manufacturers of Ethylene Dibromide
Dow Chemical U.S.A.
2030 Dow Center
Midland, Michigan
Great Lakes Chemical Corp.
P. 0. Box 2200
West Lafayette, Indiana
Ethyl Corporation
330 South Fourth Street
Richmond, Virginia
PPG Industries, Inc.
One Gateway Center
Pittsburgh, Pennsylvania
							
					
						Page last reviewed:  June 6, 2014					Content source: 	National Institute for Occupational Safety and Health homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue